Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest forms of cancer, with a particularly grim prognosis for patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have made a significant breakthrough in understanding the mechanisms that drive this aggressive disease. Led by former graduate student Alexander Kral and under the guidance of Professor Adrian Krainer, the team has identified a complex interaction between three proteins that may hold the key to more effective treatments.
In a 2023 study, the Krainer lab uncovered how the protein SRSF1 initiates the development of PDAC tumors. Building on that foundation, Kral and his team discovered that SRSF1 functions as part of a regulatory circuit involving two other critical players: Aurora kinase A (AURKA) and the oncogene MYC. This circuit significantly contributes to the aggressive progression of PDAC.
“Our theory was that some of the changes caused by increased levels of SRSF1 were playing a role in the accelerated tumor growth we were seeing,” Kral stated. The research revealed that SRSF1 regulates AURKA via a process called alternative splicing, which in turn boosts the production of AURKA. This increase stabilizes and protects MYC, leading to a feedback loop that further elevates SRSF1 levels.
Disrupting the Circuit for Therapeutic Gain
The researchers describe this mechanism as a critical circuit, likening it to a chain reaction that fuels tumor growth. “Bits and pieces of this circuit were known previously, but we didn’t have the full picture until now,” Krainer explained. The identification of alternative splicing in AURKA presents new opportunities for therapeutic intervention.
To target this circuit, the team developed an antisense oligonucleotide (ASO), a type of molecule designed to modify gene expression. Known for creating Spinraza, the first FDA-approved treatment for spinal muscular atrophy, the Krainer lab applied their expertise to obstruct AURKA’s alternative splicing. The results were promising; the ASO not only interfered with AURKA but effectively dismantled the entire oncogenic circuit.
This breakthrough led to a substantial reduction in the viability of tumor cells and triggered a form of programmed cell death known as apoptosis. “It’s like killing three birds with one stone,” Krainer remarked, highlighting that targeting AURKA splicing with their ASO resulted in the loss of both SRSF1 and MYC.
Future Prospects and Clinical Applications
While the research is still in its early stages, the implications are profound. The Krainer lab is diligently working to refine their ASO for potential clinical applications. Although practical treatments for patients remain a distant goal, Krainer emphasizes the importance of foundational research in paving the way for future breakthroughs.
“Every clinical breakthrough begins with such basic research,” he noted, reflecting on the journey of Spinraza, which has saved countless lives. The hope is that similar advancements can be achieved in the fight against pancreatic cancer.
As the global medical community continues to grapple with the challenges posed by PDAC, this new understanding of its underlying mechanisms offers a beacon of hope for patients and clinicians alike.
